Last reviewed · How we verify
V110, pneumococcal vaccine polyvalent
V110, pneumococcal vaccine polyvalent, stimulates the body's immune system to produce antibodies against pneumococcal bacteria.
V110, pneumococcal vaccine polyvalent, stimulates the body's immune system to produce antibodies against pneumococcal bacteria. Used for Prevention of invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F.
At a glance
| Generic name | V110, pneumococcal vaccine polyvalent |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This vaccine works by introducing inactivated pneumococcal bacteria to the body, which triggers an immune response and the production of antibodies that can help protect against future infections. The immune system then remembers these bacteria and can mount a more effective response if exposed to them again in the future.
Approved indications
- Prevention of invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F
Common side effects
- Pain, redness, swelling, or itching at the injection site
- Fatigue
- Headache
Key clinical trials
- Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007) (PHASE3)
- Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011) (PHASE3)
- A Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |